Utama › Karsinoma Sel Skuamosa Kepala dan Leher › Michigan › Detroit
Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Detroit, MI
15 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi dalam dan sekitar Detroit (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Mengambil pesertaFasa 3
- Karmanos Cancer Institute, Detroit
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Mengambil pesertaFasa 1/2
- Karmanos Cancer Institute, Detroit
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Mengambil pesertaFasa 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Mengambil pesertaKajian pemerhatian
- Karmanos Cancer Institute, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Mengambil pesertaFasa 2/3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Mengambil pesertaFasa 2
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of DM005 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Henry Ford Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Henry Ford Cancer Institute, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Mengambil pesertaFasa 1
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Henry Ford Health System, Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 129, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Mengambil pesertaFasa 1/2
- Karmanos Cancer Institute, Detroit
Kajian Karsinoma Sel Skuamosa Kepala dan Leher di bandar lain
- Houston, TX47 kajian
- Los Angeles, CA42 kajian
- Boston, MA40 kajian
- New York City, NY39 kajian
- Nashville, TN39 kajian
- St. Louis, MO28 kajian
- Arlington, VA26 kajian
- Philadelphia, PA26 kajian
- Chicago, IL26 kajian
- Atlanta, GA24 kajian
- San Antonio, TX22 kajian
- New Haven, CT22 kajian
Kajian lain di Detroit
- Kanser Paru-paru Bukan Sel Kecil44 kajian
- Kanser Payudara33 kajian
- Kanser (semua jenis)29 kajian
- Kanser Kolorektal26 kajian
- Kanser Ovari26 kajian
- Kanser Metastatik24 kajian
- Kanser Prostat22 kajian
- Kanser Endometrium21 kajian
- Kanser Paru-paru20 kajian
- Mieloma Pelbagai19 kajian
- Kanser Perut16 kajian
- Leukemia Mieloid Akut14 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.